Literature DB >> 11116146

The epidermal growth factor receptor engages receptor interacting protein and nuclear factor-kappa B (NF-kappa B)-inducing kinase to activate NF-kappa B. Identification of a novel receptor-tyrosine kinase signalosome.

A A Habib1, S Chatterjee, S K Park, R R Ratan, S Lefebvre, T Vartanian.   

Abstract

The transcription factor nuclear factor-kappaB (NF-kappaB) is activated by a diverse number of stimuli including tumor necrosis factor-alpha, interleukin-1, UV irradiation, viruses, as well as receptor tyrosine kinases such as the epidermal growth factor receptor (EGFR). NF-kappaB activation by the tumor necrosis factor receptor (TNFR) involves the formation of a multiprotein complex termed a signalosome. Although previous studies have shown that the activated EGFR can induce NF-kappaB, the mechanism of this activation remains unknown. In this study, we identify components of the signalosome formed by the activated EGFR required to activate NF-kappaB and show that, although the activated EGFR uses mechanisms similar to the TNFR, it recruits a distinct signalosome. We show the EGFR forms a complex with a TNFR-interacting protein (RIP), which plays a key role in TNFR-induced NF-kappaB activation, but not with TRADD, an adaptor protein which serves to recruit RIP to the TNFR. Furthermore, we show that the EGFR associates with NF-kappaB-inducing kinase (NIK) and provide evidence suggesting multiprotein complex formation between the EGFR, RIP, and NIK. Using a dominant negative NIK mutant, we show that NIK activation is required for EGFR-mediated NF-kappaB induction. We also show that a S32/36 IkappaBalpha mutant blocks EGFR-induced NF-kappaB activation. Our studies also suggest that a high level of EGFR expression, a frequent occurrence in human tumors, is optimal for epidermal growth factor-induced NF-kappaB activation. Finally, although protein kinase B/Akt has been implicated in tumor necrosis factor and PDGF-induced NF-kappaB activation, our studies do not support a role for this protein in EGFR-induced NF-kappaB activation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11116146     DOI: 10.1074/jbc.M008458200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  42 in total

1.  FER tyrosine kinase (FER) overexpression mediates resistance to quinacrine through EGF-dependent activation of NF-kappaB.

Authors:  Canhui Guo; George R Stark
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-25       Impact factor: 11.205

Review 2.  NF-kappaB in pancreatic cancer.

Authors:  Guido M Sclabas; Shuichi Fujioka; Christian Schmidt; Douglas B Evans; Paul J Chiao
Journal:  Int J Gastrointest Cancer       Date:  2003

3.  Cross-talk between receptor tyrosine kinase and tumor necrosis factor-α signaling networks regulates apoptosis but not proliferation.

Authors:  Elsa M Beyer; Gavin MacBeath
Journal:  Mol Cell Proteomics       Date:  2012-02-08       Impact factor: 5.911

4.  NFKBIA deletion in glioblastomas.

Authors:  Markus Bredel; Denise M Scholtens; Ajay K Yadav; Angel A Alvarez; Jaclyn J Renfrow; James P Chandler; Irene L Y Yu; Maria S Carro; Fangping Dai; Michael J Tagge; Roberto Ferrarese; Claudia Bredel; Heidi S Phillips; Paul J Lukac; Pierre A Robe; Astrid Weyerbrock; Hannes Vogel; Steven Dubner; Bret Mobley; Xiaolin He; Adrienne C Scheck; Branimir I Sikic; Kenneth D Aldape; Arnab Chakravarti; Griffith R Harsh
Journal:  N Engl J Med       Date:  2010-12-22       Impact factor: 91.245

5.  Activation of NF-kappaB is essential for hepatocyte growth factor-mediated proliferation and tubulogenesis.

Authors:  Markus Müller; Alessandro Morotti; Carola Ponzetto
Journal:  Mol Cell Biol       Date:  2002-02       Impact factor: 4.272

Review 6.  Crosstalk in NF-κB signaling pathways.

Authors:  Andrea Oeckinghaus; Matthew S Hayden; Sankar Ghosh
Journal:  Nat Immunol       Date:  2011-07-19       Impact factor: 25.606

7.  NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer.

Authors:  Collin M Blakely; Evangelos Pazarentzos; Victor Olivas; Saurabh Asthana; Jenny Jiacheng Yan; Irena Tan; Gorjan Hrustanovic; Elton Chan; Luping Lin; Dana S Neel; William Newton; Kathryn L Bobb; Timothy R Fouts; Jeffrey Meshulam; Matthew A Gubens; David M Jablons; Jeffrey R Johnson; Sourav Bandyopadhyay; Nevan J Krogan; Trever G Bivona
Journal:  Cell Rep       Date:  2015-04-02       Impact factor: 9.423

Review 8.  The multifaceted NF-kB: are there still prospects of its inhibition for clinical intervention in pediatric central nervous system tumors?

Authors:  Mariana Medeiros; Marina Ferreira Candido; Elvis Terci Valera; María Sol Brassesco
Journal:  Cell Mol Life Sci       Date:  2021-07-31       Impact factor: 9.261

9.  Her2 activates NF-kappaB and induces invasion through the canonical pathway involving IKKalpha.

Authors:  E C Merkhofer; P Cogswell; A S Baldwin
Journal:  Oncogene       Date:  2009-11-30       Impact factor: 9.867

10.  Receptor-interacting protein shuttles between cell death and survival signaling pathways.

Authors:  Pachiyappan Kamarajan; Julius Bunek; Yong Lin; Gabriel Nunez; Yvonne L Kapila
Journal:  Mol Biol Cell       Date:  2009-12-02       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.